BioPharma « Terug naar discussie overzicht

quote:

crackedtooth schreef:

[quote=GhosTWolF]
If the opt-in is exercised by Tercica, Insmed would be reimbursed 50% of its incurred development costs for the indication and further development costs would be shared 50:50. Upon subsequent commercialization, Insmed and Tercica will split profits 50:50 after accounting for relevant expenses including sales-based tiered royalties of 6%-15% to Genentech.

If the opt-in is exercised by Genentech, Insmed would be reimbursed 50% of its incurred development costs for the indication. Subsequent development costs and profits will be split 50:50, but no royalty will be owed to Tercica.

Het is wel duidelijk dat alles via TRCA gespeeld gaat worden, zodat beiden (DNA en TRCA) hier voordeel uit halen. (royalties)
[/quote]

yep alleen heeft trca niet de centjes om veel opt in te doen
:p

quote:

crackedtooth schreef:

7-Mar-2007

Costs Associated with Exit or Disposal Activities, Change in Directors or Principal Of

Item 2.05. Costs Associated with Exit or Disposal Activities.
On February 21, 2007, the Board of Directors of Insmed Incorporated (the "Company") committed to a business restructuring plan following the Company's announcement of the Settlement, Development and License Agreement with Tercica, Inc. and Genentech, Inc, which laid out the terms for settlement of all of the outstanding litigation between the parties and includes an agreement that the Company will withdraw IPLEX from the short stature market. The restructure will eliminate the Company's commercial department and downsize the Company's manufacturing facility located Boulder, Colorado resulting in an immediate reduction of approximately 34% of the Company's current workforce of 150. Employees who are affected by the restructuring have received notification of the plan and will be provided with severance payments. The Company expects to complete the restructuring plan by March 9, 2007 and that the restructure will allow its current cash reserves to fund operations into the fourth quarter of 2007. As of December 31, 2006 the Company had $24.1 million of cash on hand.

As a result of the restructuring plan, the Company estimates that it will incur a one-time restructuring charge in March 2007 of approximately $1.7 million for severance payments. The Company estimates that the $1.7 million represents the total amount of restructuring charge to be incurred including future cash expenditures. The charges that the Company expects to incur in relation to the restructuring plan are subject to a number of assumptions, and actual results may materially differ. The Company may also incur other material charges not currently contemplated due to events that may occur as a result of, or associated with, the restructuring plan.

Item 5.02 Departure of Directors or Principal Officers
As a result of the restructure, on March 7, 2007, the Company announced that Mr. Philip J. Young, Executive Vice President and Chief Business Officer will be leaving the company effective immediately.

Item 9.01. Financial Statements and Exhibits
d) Exhibits.

quote:

M.A.D.W. schreef:

The Company is presently conducting ongoing clinical research in patients with HIV associated Adipose Redistribution Syndrome (HARS) and Myotonic Muscular Dystrophy (MMD). The clinical trial for HARS is ongoing at the University of California, San Francisco while the MMD clinical trial is ongoing at the University of Rochester. Initial data from both trials is expected to be released in Q2 2007

Dus de fase 2 nieuws komt volgend kwartaal.

quote:

smartcard schreef:

Markt gaat open om 11u05

quote:

beur schreef:

Houdt u maar stevig vast. Dadelijk gaan we weer van alles beleven. Spanning en sensatie met Innie. Nieuwe ronde, nieuwe kansen.

quote:

ludwig mack schreef:

[quote=beur]
Houdt u maar stevig vast. Dadelijk gaan we weer van alles beleven. Spanning en sensatie met Innie. Nieuwe ronde, nieuwe kansen.
[/quote]

volgens mij blijft het rustig en zit je in het verkeerde draadje :)

quote:

beur schreef:

[quote=ludwig mack]
[quote=beur]
Houdt u maar stevig vast. Dadelijk gaan we weer van alles beleven. Spanning en sensatie met Innie. Nieuwe ronde, nieuwe kansen.
[/quote]

volgens mij blijft het rustig en zit je in het verkeerde draadje :)
[/quote]
Nee Ludwig, dadelijk gaat Insmed vertellen over het herstructureringsplan en we zullen zien wat dit voor de koers op levert!

quote:

sethonno schreef:

beur rot toch op.